Phase II study of chlorozotocin in malignant melanoma: a Southeastern Cancer Study Group report.
| Autor: | Van Amburg AL 3rd, Presant CA, Burns D |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cancer treatment reports [Cancer Treat Rep] 1982 Jun; Vol. 66 (6), pp. 1431-3. |
| Abstrakt: | Seventy-nine patients with metastatic melanoma received chlorozotocin (150 mg/m2) every 6 weeks. Two complete and five partial responses were observed: 18% in patients who had not previously received chemotherapy and 6% in previously drug-resistant patients. Dose-limiting toxic effects were vomiting and myelosuppression. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|